Characterization of tissue and plasma glycosaminoglycans during experimental AA amyloidosis and acute inflammation. Qualitative and quantitative analysis.
Qualitative and quantitative methods were used to determine changes in glycosaminoglycans (GAGs) in the spleen and plasma during initial stages of experimental amyloidosis and acute inflammation. GAG deposition in the spleen during the early stages of amyloidosis consists of a 16-fold heparin and heparan sulfate increase. Though splenic weights do increase during protracted inflammation only minor changes arise in splenic GAGs in the absence of amyloid deposition. An overall increase in plasma GAGs, consisting of a 4.5-fold chondroitin-4-sulphate increase, occurred at the time of GAG deposition in the tissues (spleen, liver) and probably accounts for the minor GAG changes seen in the spleen during inflammation. The time course of splenic heparin/heparan sulfate increase during amyloid deposition coincides with the histochemical changes previously described. Plasma GAG changes follow a pattern similar to that of acute phase protein reactants. The results suggest that GAG metabolism, in particular heparin/heparan sulfate, are intimately involved in the process of AA amyloidogenesis.
D000208:Acute Disease; D000686:Amyloidosis / Q000209:etiology / Q000378:metabolism*; D000818:Animals; D004586:Electrophoresis; D005260:Female; D006023:Glycoproteins / Q000494:pharmacology; D006025:Glycosaminoglycans / Q000032:analysis* / Q000097:blood; D007249:Inflammation / Q000378:metabolism*; D051379:Mice; D008808:Mice, Inbred CBA; D000685:Serum Amyloid A Protein / Q000032:analysis*; D012835:Silver Nitrate / Q000494:pharmacology; D013154:Spleen / Q000032:analysis
D006023:Glycoproteins; D006025:Glycosaminoglycans; D000685:Serum Amyloid A Protein; C046748:amyloid enhancing factor; D012835:Silver Nitrate